NCT00174811终止3 期
Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of Telithromycin 25 mg/kg Given Once Daily for 5 or 10 Days Depending on Age and Previous Treatment History Versus Cefuroxime Axetil 15 mg/kg, Given Twice Daily for 10 Days, in Children With Acute Otitis Media
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Sanofi
- 入组人数
- 639
- 试验地点
- 3
- 主要终点
- Clinical cure at the posttherapy/test-of-cure (TOC) Visit 3 (Day 13-17).
研究概览
简要总结
The clinical activity of telithromycin vs. cefuroxime in children with acute infections of the middle ear, ages 6 months to 59 months old will be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 6 Months 至 59 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects ≥6 months and <59 months of age with AOM;
- •Recent (within the last 72 hours) and rapid onset of AOM signs and symptoms;
- •The presence of MEF on otoscopy indicated by a bulging tympanic membrane;
- •Otalgia or ear tugging or touching within the last 24 hours that interferes with or precludes normal activity or sleep;
- •At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability;
- •Tympanocentesis performed per protocol with MEF sample collected;
- •Informed consent must be obtained in writing at enrollment into the study, from the child's parent/legally authorized representative. The parent/legally authorized representative has agreed to provide follow-up information and arrange for all scheduled visits, even in the event that study medication is discontinued.
排除标准
- •Uncertain diagnosis of AOM or signs and symptoms of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days;
- •Otorrhea or tympanostomy tube present in either ear at study entry;
- •Otitis externa;
- •Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection;
- •Known congenital prolonged QT syndrome;
- •Uncorrected hypokalemia (≤3 mmol/L [mEq/L]), hypomagnesemia (based on laboratory assessment), bradycardia (<50 bpm);
- •Myasthenia gravis;
- •Known impaired renal function, as shown by the creatinine clearance ≤25 mL/min;
- •Any medical condition (including developmental disorders, visual disorders, or ocular abnormalities) that, in the opinion of the investigator, would interfere with implementation of the protocol or interpretation of the study results;
- •The subject:
- •Is being treated with drugs not permitted by the study protocol ie, cisapride, pimozide, astemizole, terfenadine, ergotamine, dihydroergotamine, class IA (eg, quinidine and procainamide) or Class III (eg, dofetilide) antiarrhythmic agents, simvastatin, lovastatin and atorvastatin;
- •Is currently being treated with systemic antibacterials or has been treated with systemic antibacterials within 5 days prior to enrollment;
- •Has been treated with any investigational medication within the last 30 days; or
- •Has been treated with rifampicin, phenytoin, carbamazepine, or St. John's wort within the last 2 weeks.
- •History of hypersensitivity or intolerance to macrolides, penicillins, or cephalosporins;
- •Previous enrollment in this study or previous treatment with telithromycin;
- •Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol.
结局指标
主要结局
Clinical cure at the posttherapy/test-of-cure (TOC) Visit 3 (Day 13-17).
次要结局
- Time to symptom resolution (TSR).
- Clinical cure by protocol-defined causative pathogen isolated at baseline·
- Bacteriological eradication in population with protocol-defined causative pathogen isolated at baseline.
- Safety of telithromycin versus cefuroxime axetil.
- Plasma telithromycin concentrations during treatment in the subpopulation of subjects participating in the pharmacokinetic (PK) substudy.
- Health resource utilization and impact on usual activities.
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)Urinary Tract InfectionsSoft Tissue InfectionsBacterial PneumoniaNCT00451386Merck Sharp & Dohme LLC400
终止
3 期
An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract InfectionsUrinary Tract InfectionNCT02302092Takeda13
已完成
2 期
Comparison of cefixime and azithromycin in pediatric dysenteryDysentery.Other gastroenteritis and colitis of infectious and unspecified originIRCT2014091013366N4Arak University of Medical Sciences116
已完成
4 期
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin InfectionsStaphylococcal InfectionAbscessStaphylococcal Skin InfectionFolliculitisNCT00352612Aaron Chen200
已完成
4 期
Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPDBronchitis, ChronicNCT00538148Sanofi668